Zanidatamab (ZW25), a HER2-Targeted Bispecific Antibody, in Combination With Chemotherapy and Tislelizumab in Patients With Advanced HER2-Positive Gastric/Gastroesophageal Junction Adenocarcinoma: Updated Results From a Phase 1b/2 Study
Zanidatamab (ZW25), a HER2-Targeted Bispecific Antibody, in Combination With Chemotherapy and Tislelizumab in Patients With Advanced HER2-Positive Gastric/Gastroesophageal Junction Adenocarcinoma: Updated Results From a Phase 1b/2 Study
Preliminary Results From a Phase 1 Study Using the Bispecific, Human Epidermal Growth Factor 2 (HER2)-targeting Antibody-drug Conjugate (ADC) Zanidatamab Zovodotin (ZW49) in Solid Cancers
Preliminary Results From a Phase 1 Study Using the Bispecific, Human Epidermal Growth Factor 2 (HER2)-targeting Antibody-drug Conjugate (ADC) Zanidatamab Zovodotin (ZW49) in Solid Cancers
Phase (Ph) 2 Study of Zanidatamab + Chemotherapy (chemo) in First Line (1L) HER2 expressing Gastroesophageal Adenocarcinoma (GEA)
Phase (Ph) 2 Study of Zanidatamab + Chemotherapy (chemo) in First Line (1L) HER2 expressing Gastroesophageal Adenocarcinoma (GEA)
